Quick Answer
Silence Therapeutics plc reported Revenue From Contract With Customer Excluding Assessed Tax of $559.0 thousand for the year ending 2025.
- Silence Therapeutics plc showed a decrease of -98.7% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Silence Therapeutics plc's annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 4 years of available data (2022 to 2025), Silence Therapeutics plc's Revenue From Contract With Customer Excluding Assessed Tax has declined by 97.4%.
- Historical annual values: Fiscal year 2025: $559.0 thousand | Fiscal year 2024: $43.26 million | Fiscal year 2023: $31.64 million | Fiscal year 2022: $21.66 million.
- Data sourced from SEC EDGAR public filings as of June 24, 2026.
Last verified: